

Agile Therapeutics Investor Relations Department 101 Poor Farm Road Princeton, NJ 08540 United States

Visit IR website ☐ Sign-up for email alerts ☐

NASDAQ: AGRX	
Last Trade:	3.40
Trade Time:	4:00 PM ET Aug 18, 2017
Change:	-0.08 🖶 (-2.299%)
Day Range	3.31 - 3.44
52-Week Range	1.82 - 8.15
Volume	78,760

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## **Company Profile**

Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15. is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability.

#### **Stock Performance**



### Press Releases [View all]

Aug 16, 2017

Agile Therapeutics to Present at Liolios 6th Annual Gateway Conference

Aug 3, 2017

Agile Therapeutics Announces Pricing of Its
Public Offering of Common Stock

Aug 2, 2017

Agile Therapeutics Announces Proposed
Offering of Common Stock

Jul 28, 2017

Agile Therapeutics Reports Second Quarter 2017 Financial Results

Jul 27, 2017

Agile Therapeutics Announces FDA

Acceptance of the NDA Resubmission of
Twirla®

### Upcoming Events [View all]

Sep 7, 2017 8:00 AM PT

Agile Therapeutics to Present at Liolios 6th

Annual Gateway Conference

Oct 10, 2017 11:00 AM ET Agile Analyst Day

# Financials [View all]

Mar 15, 2017 Annual Report (10-K)

Apr 24, 2017 Proxy Statement (DEF 14A)

Jul 28, 2017

Quarterly Report (10-Q)

May 8, 2017

Quarterly Report (10-Q)

Nov 7, 2016

Quarterly Report (10-Q)